BioXcel Therapeutics(NASDAQ) BTAI

Market Cap$24.48M

Since IPO (2018)-100%

5 Year-100%

1 Year-45%

1 Month-44%

$0.82

+3.22%

+0.03Today

After hours$0.82+$0.00 (+0.13%)

BioXcel Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.79	2026-07-30

BioXcel Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-8.9%	USD 0.87	2026-07-23
1 month	-43.77%	USD 1.41	2026-06-30
3 month	-33.93%	USD 1.20	2026-05-01
Year to date	-50.45%	USD 1.60	2025-12-31
1 year	-44.56%	USD 1.43	2025-07-30
3 year	-99.46%	USD 146.24	2023-07-31
5 year	-99.81%	USD 409.44	2021-07-30
Since inception	-99.55%	USD 176.48	2018-03-08

BioXcel Therapeutics Financials at a Glance

Market Cap

$24.48M

Revenue (TTM)

$680.00K

Net Income (TTM)

-$75.33M

EPS (TTM)

-$6.19

P/E Ratio

-0.13

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$0.82

Volume

499,305.393

Open

$0.79

Price

$0.82

Volume

499,305.393

Open

$0.79

Previous Close

$0.81

Daily Range

$0.78 - $0.84

52-Week Range

$0.74 - $8.08

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$0.82

Volume

499,305.393

Open

$0.79

Previous Close

$0.81

Daily Range

$0.78 - $0.84

52-Week Range

$0.74 - $8.08

Estimated Earnings Date

Aug 11, 2026

BTAI News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioXcel Therapeutics

BioXcel Therapeutics develops medicines for mental health and cancer. Its main product helps calm agitation in adults with certain psychiatric conditions. The company uses artificial intelligence to find new uses for existing drugs.

What’s in the Medicine Cabinet?

IGALMI (BXCL501): FDA-approved film for calming agitation in adults with schizophrenia or bipolar disorder; 100% of 2025 revenue.
BXCL501 (pipeline): Investigational use for agitation in Alzheimer’s, depression, opioid withdrawal, and stress disorders; no current revenue.
BXCL502: In development for chronic agitation in dementia; not yet generating revenue.
BXCL701: Oral drug in trials for aggressive prostate and pancreatic cancers; no revenue contribution.

Growth and Expansion: The Road So Far

Launched IGALMI in 2022 for hospital use in the U.S.
Completed SERENITY At-Home Phase 3 trial for BXCL501 in 2025.
Raised $34.5 million via at-the-market equity sales in 2025.
Raised $7.8 million in a direct offering in March 2026.
Reduced workforce by about 60% in 2023, with further cuts in 2024.

What Makes BioXcel Stand Out?

BioXcel uses artificial intelligence to identify new uses for existing drugs, aiming to speed up development and reduce costs. Its focus is on treating agitation in mental health and neurodegenerative conditions, areas with few effective options. The company holds patents for its main products, supporting its position in niche markets.

Five Things You Need to Know

Revenue was $98,000 in Q3 2025, down 54.2% from Q3 2024.
Net loss was $14 million in Q3 2025, improved 8.9% year-over-year.
All 2025 revenue came from IGALMI; no international sales reported.
Cash used in operations was $19 million in Q3 2025, up 15% year-over-year.
Debt stood at $112.2 million as of December 2025, with cash of $28.8 million.

Bottom Line

BioXcel has narrowed its focus to core neuroscience products and cash preservation. The company faces financial challenges but continues to develop treatments for agitation and cancer.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Vimal D. Mehta, PhD

Website

www.bioxceltherapeutics.com

Headquarters

New Haven, CT 06511, US

BTAI Financials

Key Financial Metrics (TTM)

Gross Margin

27.79%

Operating Margin

-7395.00%

Net Income Margin

-11078.53%

Return on Equity

75.79%

Return on Capital

-354.09%

Return on Assets

-221.41%

Earnings Yield

-7.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.48M

Shares Outstanding

30.88M

Volume

499.31K

Avg. Volume

916.08K

Financials (TTM)

Gross Profit

$189.00K

Operating Income

-$50.29M

EBITDA

-$57.86M

Operating Cash Flow

-$57.38M

Capital Expenditure

$0.00

Free Cash Flow

-$57.38M

Cash & ST Invst.

$17.18M

Total Debt

$100.29M

BioXcel Therapeutics Performance Analysis

BioXcel Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 375,000	N/A
2023	2023-12-31	USD 1,380,000	268.0%
2024	2024-12-31	USD 2,266,000	64.2%
2025	2025-12-31	USD 642,000	-71.7%

BioXcel Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-28.6%
Q3	2025-09-30	-18.3%
Q4	2025-12-31	161.2%
Q1	2026-03-31	-19.5%

BioXcel Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -94.67	45.9%
2023	2023-12-31	USD -98.35	3.9%
2024	2024-12-31	USD -23.51	-76.1%
2025	2025-12-31	USD -5.73	-75.6%

BioXcel Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-63.3%
Q3	2025-09-30	11.0%
Q4	2025-12-31	52.8%
Q1	2026-03-31	-1.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$206.00K

+22.6%

Gross Profit

-$135.00K

-187.7%

Gross Margin

-65.53%

N/A

Market Cap

$24.48M

N/A

Market Cap/Employee

$844.13K

N/A

Employees

N/A

Net Income

-$12.69M

-75.0%

EBITDA

-$8.44M

-164.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$17.18M

-44.6%

Total Debt

$100.29M

-5.3%

Accounts Receivable

$216.00K

N/A

Inventory

$500.00K

-22.1%

Long Term Debt

$77.86M

-22.1%

Short Term Debt

$22.43M

+276.5%

Return on Assets

-2.21%

N/A

Return on Invested Capital

2.40%

N/A

Free Cash Flow

-$11.81M

+1.9%

Operating Cash Flow

-$11.81M

+1.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CELUCelularity Inc.

CELUCelularity Inc.$0.64-6.57%

EVAXEvaxion Biotech A/S

EVAXEvaxion Biotech A/S$2.82-0.35%

ANVSAnnovis Bio, Inc.

ANVSAnnovis Bio, Inc.$1.75-1.13%

MURAMural Oncology plc

MURAMural Oncology plc$2.04+0.00%

VERUVeru Inc.

VERUVeru Inc.$2.24+0.90%

GBIOGeneration Bio Co.

GBIOGeneration Bio Co.$5.34+0.00%

RVPHReviva Pharmaceuticals Holdings, Inc.

RVPHReviva Pharmaceuticals Holdings, Inc.$0.44+0.08%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About BTAI

What is the current price of BioXcel Therapeutics?

BioXcel Therapeutics is trading at $0.81 per share.

What is the 52-week range for BioXcel Therapeutics?

Over the past 52 weeks, BioXcel Therapeutics has traded between $0.74 and $8.08.

How much debt does BioXcel Therapeutics have?

As of the most recent reporting period, BioXcel Therapeutics reported total debt of $100.29M.

How much cash does BioXcel Therapeutics have on hand?

BioXcel Therapeutics reported $17.18M in cash and cash equivalents in its most recent financial results.

What is BioXcel Therapeutics’s dividend yield?

BioXcel Therapeutics does not currently have a dividend yield.

BioXcel Therapeutics(NASDAQ) BTAI

BioXcel Therapeutics Financials at a Glance

BTAI News

Why BioXcel Therapeutics Stock Flopped Again Today

Why BioXcel Therapeutics Stock Is Getting Crushed Today

Why BioXcel Therapeutics Stock Was Bouncing Back This Week

Why Shares of BioXcel Therapeutics Are Plunging Thursday

Why Shares of BioXcel Therapeutics Are Dropping Thursday

Why BioXcel Therapeutics Stock Marched Higher Today

Why BioXCel Therapeutics Stock Jumped This Week

Why BioXcel Therapeutics Stock Triumphed This Week

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BioXcel Therapeutics

What’s in the Medicine Cabinet?

Growth and Expansion: The Road So Far

What Makes BioXcel Stand Out?

Five Things You Need to Know

Bottom Line

BTAI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BioXcel Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BTAI

What is the current price of BioXcel Therapeutics?

What is the 52-week range for BioXcel Therapeutics?

How much debt does BioXcel Therapeutics have?

How much cash does BioXcel Therapeutics have on hand?

What is BioXcel Therapeutics’s dividend yield?

Premium Investing Services